Total Renal Care, Inc. is a medicare approved dialysis facility center in Etowah, Tennessee and it has 16 dialysis stations. It is located in Mcminn county at 109 Grady Rd, Etowah, TN, 37331. You can reach out to the office of Total Renal Care, Inc. at (423) 263-3666. This dialysis clinic is managed and/or owned by Davita. Total Renal Care, Inc. has the following ownership type - Profit. It was first certified by medicare in November, 1992. The medicare id for this facility is 442715 and it accepts patients under medicare ESRD program.
| Name | Total Renal Care, Inc. |
|---|---|
| Location | 109 Grady Rd, Etowah, Tennessee |
| No. of Dialysis Stations | 16 |
| Medicare ID | 442715 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 109 Grady Rd, Etowah, Tennessee, 37331 | |
| (423) 263-3666 | |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
| NPI Number | 1023296837 |
| Organization Name | Woods Regional Dialysis Center |
| Doing Business As | Doctors Hospital Of Mcminn County, Llc |
| Address | 886 Highway 411 N Etowah, Tennessee, 37331 |
| Phone Number | (423) 263-3600 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
| NPI Number | 1184998270 |
| Organization Name | Etowah Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 109 Grady Rd Etowah, Tennessee, 37331 |
| Phone Number | (423) 263-3666 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 21 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 38 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 359 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Total Renal Care, Inc. with elevated calcium levels.
| Patients with hypercalcemia | 39 |
| Hypercalcemia patient months | 371 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 36 |
| Patient months included in arterial venous fistula and catheter summaries | 279 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 76 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 28 |
| Hospitalization Rate in facility | 135.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 285.1 |
| Hospitalization Rate: Lower Confidence Limit | 68.5 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Total Renal Care, Inc. were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.8 |
| Readmission Rate: Lower Confidence Limit | 9.1 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Total Renal Care, Inc. get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .96 (As Expected) |
| SIR: Upper Confidence Limit | 3.16 |
| SIR: Lower Confidence Limit | .16 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Total Renal Care, Inc.'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 24 |
| Transfusion Rate in facility | 29.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 126.1 |
| Transfusion Rate: Lower Confidence Limit | 8.4 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Total Renal Care, Inc. lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 163 |
| Mortality Rate in facility | 19.2 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26.9 |
| Mortality Rate: Lower Confidence Limit | 13.2 |
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago
News Archive
Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.
ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials.
A research project affiliated with the University of Helsinki's Institute for Atmospheric and Earth System Research has identified serious deficiencies in the Stoffenmanager and Advanced REACH Tool occupational exposure models used for assessing chemical safety and calls for the discontinuation of their use in statutory chemical safety assessment.
Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
› Verified 3 days ago